Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA

CONCLUSION: This external validation study confirmed previous results about modeled PSA longitudinal kinetics prognostic value regarding PFS/OS in patients with mCRPC treated with taxanes. PSA.KELIM could be used to identify a subpopulation with poor prognosis, who may benefit from treatment intensification.PMID:38364191 | DOI:10.1200/CCI.23.00208

Source: Clinical Prostate Cancer - February 16, 2024 Category: Cancer & Oncology Authors: Aurore Carrot St éphane Oudard Olivier Colomban Karim Fizazi Denis Maillet Oliver Sartor Gilles Freyer Benoit You Source Type: research